



08-19-03

1653

Applicant's Docket No. MPI00-452P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: O'Keefe, Theresa L., et al.  
Application No.: 10/060,714 Group No.: 1653  
Filed: January 30, 2002 Examiner: N/A  
For: HYBRID ANTIBODIES AND USES THEREOF

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
37 C.F.R. SECTION 1.8(a) 37 C.F.R. SECTION 1.10\*

☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EL992152874US

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Date: August 18, 2003

Sean Hunziker  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-452P1RM**

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**FEE PAYMENT**

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

**METHOD OF PAYMENT OF FEE**

4. ☐ Attached is a check in the amount of \$ \_\_\_\_\_ .  
☐ Charge Account No. 501668 in the amount of \$0.00 .  
☐ A duplicate of this request is attached.

☒ If any additional fees are due, please charge Account 501668.

August 18, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Jean M. Silveri

Attorney/Agent for Applicant

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820



Practitioner's Docket No. MPI00-452P1RM

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: O'Keefe, Theresa L., et al.  
Application No.: 10/060,714                      Group No.: 1653  
Filed: January 30, 2002                      Examiner: N/A  
For: HYBRID ANTIBODIES AND USES THEREOF

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22213-1450**

**INFORMATION DISCLOSURE STATEMENT**

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Forms PTO/SB/08A and 08B (substitute for Form PTO-1449)
3. ☒ Copies of Listed Information Items Accompanying This Statement

---

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

- ☒ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***


- ☐ with sufficient postage as first class mail.                      ☒ as "Express Mail Post Office to Address"  
Mailing Label No. EL992152874US

**TRANSMISSION**

- ☐ transmitted by facsimile to the Patent and Trademark Office.

**Signature**

Date: August 18, 2003

  
Sean Hunziker  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI01-307CP1M

**Preliminary statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.


**Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

August 18, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By:



Jean M. Silveri

Registration No. 39,030

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-679-7336

Facsimile - 617-551-8820

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Sheet	1	of	4	Attorney Docket Number	MPI00-452P1RM
-------	---	----	---	------------------------	---------------

## U.S. PATENT DOCUMENTS


Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
	A1	5,846,534		British Technology Group Limited	12/08/1998	
	A2	5,877,293		Celltech Therapeutics Limited	03/02/1999	
	A3	5,929,212		Celltech Therapeutics Limited	07/27/1999	
	A4	5,885,793		Medical Research Council and Cambridge Antibody Technology Limited	03/23/1999	
	A5	5,994,510		Celltech Therapeutics Limited	11/30/1999	
	A6	6,506,881	B1	Celltech R&D Limited	01/14/2003	
	A7	5,877,425		Celltech Therapeutics Limited	10/14/1997	
	A8	5,969,108		Medical Research Council and Cambridge Antibody Technology Limited	10/19/1999	
	A9	6,331,415	B1	Genentech, Inc.	12/18/2001	
	A10	5,693,761		Protein Design Labs, Inc.	12/02/1997	
	A11	5,585,089		Protein Design Labs, Inc.	12/17/1996	
	A12	6,180,370	B1	Protein Design Labs, Inc.	01/30/2001	
	A13	4,816,567		Genentech, Inc.	03/28/1989	
	A14	5,530,101		Protein Design Labs, Inc.	06/25/1996	
	A15	5,688,946		Hoffmann La Roche, Inc.	11/18/1997	
	A16	5,565,332		Medical Research Council and Cambridge Antibody Technology Limited	10/15/1996	
	A17	5,733,743		Cambridge Antibody Technology Limited and Medical Research Council	03/31/1998	
	A18	5,858,657		Medical Research Council and Cambridge Antibody Technology Limited	01/12/1999	
	A19	5,871,907		Medical Research Council and Cambridge Antibody Technology Limited	02/16/1999	
	A20	5,872,215		Medical Research Council and Cambridge Antibody Technology Limited	02/16/1999	
	A21	5,885,793		Medical Research Council and Cambridge Antibody Technology Limited	03/23/1999	
	A22	5,962,255		Cambridge Antibody Technology Limited and Medical Research Council	10/05/1999	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Please type a plus sign (+) inside this box →



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

### Complete if Known

Application Number	10/060,714
Filing Date	January 30, 2002
First Named Inventor	O'Keefe, Theresa L., et al.
Group Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	MPI00-452P1RM


Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A23	5,969,108		Medical Research Council and Cambridge Antibody Technology Limited	10/19/1999	
	A24	6,140,471		Cambridge Antibody Technology Limited and Medical Research Council	10/31/2000	
	A25	6,172,197	B1	Medical Research Council and Cambridge Antibody Technology Limited	01/09/2001	
	A26	6,225,447	B1	Cambridge Antibody Technology Limited and Medical Research Council	05/1/2001	
	A27	6,291,650	B1	Cambridge Antibody Technology Limited and Medical Research Council	09/18/2001	
	A28	6,521,404	B1	Medical Research Council and Cambridge Antibody Technology Limited	02/18/2003	
	A29	6,544,731	B1	Medical Research Council and Cambridge Antibody Technology Limited	04/8/2003	
	A30	6,555,313	B1	Medical Research Council and Cambridge Antibody Technology Limited	04/29/2003	
	A31	6,582,915	B1	Medical Research Council and Cambridge Antibody Technology Limited	06/24/2003	
	A32	6,593,081	B1	Medical Research Council and Cambridge Antibody Technology Limited	07/15/2003	
	A33	5,859,205		Celltech Limited	01/12/1999	
	A34	5,545,403		Burroughs Wellcome Company	08/13/1996	
	A35	5,545,404		Burroughs Wellcome Company	8/13/1996	
	A36	5,545,405		Burroughs Wellcome Company	8/13/1996	
	A37	US2002/0099179	A1	Celltech Limited	07/25/2002	
	A38	US2003/0039645	A1	Celltech Limited	02/27/2003	
	A39	5,225,539		Medical Research Council	07/06/1993	
	A40	5,219,996		Celltech Limited	06/15/1993	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)  Sheet 3 of 4		<b>Complete if Known</b>	
		<b>Application Number</b>	10/060,714
		<b>Filing Date</b>	January 30, 2002
		<b>First Named Inventor</b>	O'Keefe, Theresa L., et al.
		<b>Group Art Unit</b>	1653
		<b>Examiner Name</b>	N/A
		<b>Attorney Docket Number</b>	MPI00-452P1RM


FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Code <sup>5</sup> Office <sup>3</sup> known)	Kind	Number <sup>4</sup> (if				
	B1	EP	EP0585287	B1	Cambridge Antibody Technology Limited and Medical Research Council	10/13/1999		
	B2	PCT	WO93/19172	A1	Cambridge Antibody Technology Limited and Medical Research Council	09/30/1993		
	B3	EP	EP1024191	A2	Medical Research Council and Cambridge Antibody Technology Limited	08/02/2000		
	B4	EP	EP0865492	B1	Cambridge Antibody Technology Limited	04/11/2001		
	B5	EP	EP0844306	A1	Cambridge Antibody Technology Limited and Medical Research Council	05/27/1998		
	B6	EP	EP0774511	B1	Cambridge Antibody Technology Limited and Medical Research Council	01/30/2002		
	B7	PCT	WO93/11236	A1	Medical Research Council and Cambridge Antibody Technology Limited	06/10/1996		
	B8	EP	EP0605522	B1	Medical Research Council and Cambridge Antibody Technology Limited	06/23/1999		
	B9	EP	EP0939127	A2	Protein Design Labs, Inc.	09/01/1999		
	B10	EP	EP0682040	B1	Protein Design Labs, Inc.	11/15/1995		
	B11	EP	EP0416373	A2	Hoffmann La Roche, Inc.	03/13/1991		
	B12	EP	EP0451216	B1	Protein Design Labs, Inc.	10/16/1991		
	B13	EP	EP0125023	B2	Genentech, Inc.	11/14/1984		
	B14	EP	EP0328404	B1	British Technology Group Limited	08/16/1989		
	B15	EP	EP0120694	B2	Celltech Therapeutics Limited	10/03/1984		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.



Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		<b>Application Number</b>	10/060,714		
		<b>Filing Date</b>	January 30, 2002		
		<b>First Named Inventor</b>	O'Keefe, Theresa L., et al.		
		<b>Group Art Unit</b>	1653		
		<b>Examiner Name</b>	N/A		
<b>Sheet</b>	4	<b>of</b>	4	<b>Attorney Docket Number</b>	MPI00-452P1RM

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD- YYYY)
		Code <sup>5</sup> Office <sup>3</sup> known)	Number <sup>4</sup>	(if		
	B16	EP	EP0460167	B1	Celltech Therapeutics Limited	12/11/1991
	B17	EP	EP0491031	B1	Celltech Therapeutics Limited	06/24/1992
	B18	PCT	WO92/11018		Protein Design Labs, Inc.	07/09/1992
	B19	EP	EP0460178	B1	Ortho Pharmaceutical Corporation	12/11/1991
	B20	EP	EP0516785	B1	Celltech Therapeutics Limited	12/09/1992
	B21	EP	EP0348442	B1	Celltech Limited	01/30/1990
	B22	EP	EP0347433	B1	Celltech Limited	12/27/1989
	B23	EP	EP0620276	A1	Celltech Limited	10/19/1994
	B24	EP	EP0626389	B1	Celltech Therapeutics Limited	11/30/1994
	B25	PCT	WO91/09967		Celltech Limited	07/11/1991
	B26	PCT	WO93/06231		Celltech Limited	04/01/1993
	B27	PCT	WO89/01974		Celltech Limited	03/09/1989
	B28	PCT	WO89/01783		Celltech Limited	03/09/1989
	B29	PCT	WO89/01782		Celltech Limited	03/09/189
	B30	EP	EP0481790	B1	The Wellcome Foundation Limited	02/24/1999
	B31	EP	EP0239400	B1	Medical Research Council	08/03/1994
	B32	EP	EP0626390	B1	Celltech Therapeutics Limited	11/14/2001
	B33	EP	EP0927758	A2	Celltech Therapeutics Limited	0707/1999
	B34	EP	EP0534742	B1	Celltech Therapeutics Limited	11/19/1997
	B35	EP	EP0781845	B1	Celltech Therapeutics Limited	04/02/2003
	B36	EP	EP0589877	B1	Cambridge Antibody Technology Limited and Medical Research Council	11/13/1996

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.




Please type a plus sign (+) inside this box → +

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

Application Number	10/060,714
Filing Date	January 30, 2002
First Named Inventor	O'Keefe, Theresa L., et al.
Group Art Unit	1653
Examiner Name	N/A
Attorney Docket Number	MPI00-452P1RM

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	T <sup>2</sup>
	C1	Riechmann, L., et al., "Reshaping human antibodies for thereapy", Nature, Volume 332, pages 323-327 (March 24, 1988)	
	C2	Hale, G., et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody Campath-1H", Lancet, Volume 2, Issue 8625, pages 1394-1399 (December 17, 1988)	

Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation design number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.